Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay. The care process model is a combination of optimal IV fluid management, early feeding, early ambulation, patient education, and pain management.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Intermountain Health Care, Inc.
• Collaborator: Cubist Pharmaceuticals LLC
• Treatments: Alvimopan

Criteria

Inclusion Criteria:

1. Age > 18

2. Patient scheduled to receive opioid-based postoperative pain management ≥ 48 hrs

3. Elective colon/rectal resection with anastomosis as primary procedure

4. Patient enrolled in multidisciplinary colon care process

Exclusion Criteria:

1. Pregnancy or lactation

2. Chronic opioid use or > 3 doses in 7 days prior to surgery

3. History of multiple previous abdominal operations, gastrectomy, bariatric surgery, short bowel syndrome

4. Complete bowel obstruction

5. Patients with end-stage renal disease as defined by the need for dialysis and the commonly accepted threshold for dialysis is a Glomerular Filtration Rate of < 15.

6. Patients with severe hepatic impairment (Childs-Pugh class C)

7. ASA 4 or 5 (ASA 4 s incapacitating systemic disease that is a constant threat to life)

8. Non-English speaking patients